DIAGNOS Inc. announced that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during third quarter 2024. These additions to DIAGNOS? service will provide its customers with a flexible AI-assisted image processing and analysis solution for the detection of a wide range of retinopathies in a general population.

Specifically, the new modules aim to assist health care professionals in identifying generally abnormal Optical Coherence Tomography retinal images, and in the grading of Fundus images as it relates to signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), or HR (Hypertensive retinopathy). These new AI analytic modules will provide DIAGNOS with the opportunity to grow its revenue faster. The modernisation of its Health Canada license was required by both current clients, the Quebec government as well as being a pre-requisite by Essilor Luxottica in order to distribute its services in Canada, as well as for a future US market.

DIAGNOS is also working towards its ISO 27001 Cyber Security application, a certification that is requested from its customers and prospects.